Paul Schramek
Overview
Explore the profile of Paul Schramek including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
26
Citations
188
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Niedersuss-Beke D, Puntus T, Kunit T, Grunberger B, Lamche M, Loidl W, et al.
Oncology
. 2017 Apr;
93(1):36-42.
PMID: 28399521
Background: Neoadjuvant chemotherapy with methotrexate-vinblastine-doxorubicin-cisplatin (MVAC) is the standard of care for muscle-invasive urothelial bladder cancer. Gemcitabine plus cisplatin (GC) shows similar efficacy with less toxicity in the metastatic setting...
2.
Martini T, Gilfrich C, Mayr R, Burger M, Pycha A, Aziz A, et al.
Clin Genitourin Cancer
. 2016 Oct;
15(3):356-362.
PMID: 27765613
Introduction: Guidelines recommend neoadjuvant chemotherapy (NAC) before radical cystectomy (RC) in patients with urothelial carcinoma of the bladder in clinical stages T2-T4a, cN0M0. We examined the frequency and current practice...
3.
Hiess M, Ponholzer A, Lamche M, Schramek P, Seitz C
Wien Med Wochenschr
. 2014 Jun;
164(15-16):297-301.
PMID: 24898195
The objective of the present study was to evaluate perioperative complications between retropubic, endoscopic and robot-assisted radical prostatectomy on basis of a prospective maintained database using the Clavien-Dindo classification of...
4.
Ponholzer A, Trubel S, Schramek P, Wimpissinger F, Feichtinger H, Springer C, et al.
World J Urol
. 2014 Feb;
32(4):911-6.
PMID: 24510119
Purpose: To test a novel technique of processing prostate biopsy specimen by marking the peripheral end (PE) as a predictive tool for positive resection margin after radical prostatectomy (RP) or...
5.
Sooriakumaran P, Srivastava A, Shariat S, Stricker P, Ahlering T, Eden C, et al.
Eur Urol
. 2013 Dec;
66(3):450-6.
PMID: 24290695
Background: Positive surgical margins (PSMs) are a known risk factor for biochemical recurrence in patients with prostate cancer (PCa) and are potentially affected by surgical technique and volume. Objective: To...
6.
Rieken M, Kluth L, Xylinas E, Fajkovic H, Becker A, Karakiewicz P, et al.
World J Urol
. 2013 Sep;
32(4):999-1005.
PMID: 24062093
Purpose: The impact of diabetes mellitus (DM) and metformin use on biochemical recurrence (BCR) in patients treated with radical prostatectomy (RP) remains controversial. Methods: We retrospectively evaluated 6,863 patients who...
7.
Kluth L, Xylinas E, Rieken M, Chun F, Fajkovic H, Becker A, et al.
Urol Oncol
. 2013 Sep;
32(1):47.e1-8.
PMID: 24055425
Objectives: To determine if the number of lymph nodes (LNs) removed is an independent predictor of biochemical recurrence (BCR) in patients without LN metastases undergoing radical prostatectomy (RP). Material And...
8.
Passoni N, Fajkovic H, Xylinas E, Kluth L, Seitz C, Robinson B, et al.
BJU Int
. 2013 Sep;
114(4):503-10.
PMID: 24053552
Objective: To assess the prognostic role of extranodal extension (ENE) and the size of the largest lymph node (LN) metastasis in predicting early biochemical relapse (eBCR) in patients with LN...
9.
Kluth L, Abdollah F, Xylinas E, Rieken M, Fajkovic H, Sun M, et al.
Eur Urol
. 2013 Jul;
66(3):439-46.
PMID: 23850255
Background: Nodal metastasis is the strongest risk factor of disease recurrence in patients with localized prostate cancer (PCa) treated with radical prostatectomy (RP). Objective: To develop a model that allows...
10.
Ponholzer A, Lamche M, Klitsch M, Kraischits N, Hiess M, Schenner M, et al.
Anticancer Res
. 2012 Mar;
32(3):1033-6.
PMID: 22399628
Background: To evaluate the reliability of sentinel lymphadenectomy compared to extended lymphadenectomy in men undergoing radical prostatectomy (RP). Patients And Methods: A consecutive cohort of men with intermediate- to high-risk...